India is among the top two countries in terms of type 2 diabetes cases and third in terms of obesity; hence, the need for ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...